var bibbase_data = {"data":"\"Loading..\"\n\n
\n\n \n\n \n\n \n \n\n \n\n \n \n\n \n\n \n
\n generated by\n \n \"bibbase.org\"\n\n \n
\n \n\n
\n\n \n\n\n
\n\n Excellent! Next you can\n create a new website with this list, or\n embed it in an existing web page by copying & pasting\n any of the following snippets.\n\n
\n JavaScript\n (easiest)\n
\n \n <script src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fgroups%2F2170577%2Fitems%3Fkey%3D1is90UKd14sB6jEMsXDPR9JR%26format%3Dbibtex%26limit%3D100&jsonp=1&jsonp=1\"></script>\n \n
\n\n PHP\n
\n \n <?php\n $contents = file_get_contents(\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fgroups%2F2170577%2Fitems%3Fkey%3D1is90UKd14sB6jEMsXDPR9JR%26format%3Dbibtex%26limit%3D100&jsonp=1\");\n print_r($contents);\n ?>\n \n
\n\n iFrame\n (not recommended)\n
\n \n <iframe src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fgroups%2F2170577%2Fitems%3Fkey%3D1is90UKd14sB6jEMsXDPR9JR%26format%3Dbibtex%26limit%3D100&jsonp=1\"></iframe>\n \n
\n\n

\n For more details see the documention.\n

\n
\n
\n\n
\n\n This is a preview! To use this list on your own web site\n or create a new web site from it,\n create a free account. The file will be added\n and you will be able to edit it in the File Manager.\n We will show you instructions once you've created your account.\n
\n\n
\n\n

To the site owner:

\n\n

Action required! Mendeley is changing its\n API. In order to keep using Mendeley with BibBase past April\n 14th, you need to:\n

    \n
  1. renew the authorization for BibBase on Mendeley, and
    2. \n
  2. update the BibBase URL\n in your page the same way you did when you initially set up\n this page.\n
    3. \n
\n

\n\n

\n \n \n Fix it now\n

\n
\n\n
\n\n\n
\n \n \n
\n
\n  \n 2023\n \n \n (2)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Schizoaffective Disorder.\n \n \n \n \n\n\n \n Wy, T. J. P.; and Saadabadi, A.\n\n\n \n\n\n\n In StatPearls. StatPearls Publishing, Treasure Island (FL), 2023.\n \n\n\n\n
\n\n\n\n \n \n \"SchizoaffectivePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@incollection{wy_schizoaffective_2023,\n\taddress = {Treasure Island (FL)},\n\ttitle = {Schizoaffective {Disorder}},\n\tcopyright = {Copyright © 2023, StatPearls Publishing LLC.},\n\turl = {http://www.ncbi.nlm.nih.gov/books/NBK541012/},\n\tabstract = {Schizoaffective disorder is one of the most misdiagnosed psychiatric disorders in clinical practice. In fact, some researchers have proposed revisions to the diagnostic criteria, and others have suggested removing the diagnosis altogether from the DSM-5. There were significant concerns regarding the reliability and utility of the diagnosis when it was first introduced in the DSM. The challenges lie within the diagnostic criteria itself since the disorder is part of a spectrum that shares criteria with many other prominent psychiatric disorders found in clinical practice.},\n\tlanguage = {eng},\n\turldate = {2023-03-21},\n\tbooktitle = {{StatPearls}},\n\tpublisher = {StatPearls Publishing},\n\tauthor = {Wy, Tom Joshua P. and Saadabadi, Abdolreza},\n\tyear = {2023},\n\tpmid = {31082056},\n\tkeywords = {Documents généraux sur les troubles concomitants},\n}\n\n
\n
\n\n\n
\n Schizoaffective disorder is one of the most misdiagnosed psychiatric disorders in clinical practice. In fact, some researchers have proposed revisions to the diagnostic criteria, and others have suggested removing the diagnosis altogether from the DSM-5. There were significant concerns regarding the reliability and utility of the diagnosis when it was first introduced in the DSM. The challenges lie within the diagnostic criteria itself since the disorder is part of a spectrum that shares criteria with many other prominent psychiatric disorders found in clinical practice.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Aspects légaux de la psychiatrie au Québec.\n \n \n \n \n\n\n \n CIUSSS du Centre-Ouest de l'Île de Montréal\n\n\n \n\n\n\n January 2023.\n \n\n\n\n
\n\n\n\n \n \n \"AspectsPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{ciusss_du_centre-ouest_de_lile_de_montreal_aspects_2023,\n\ttitle = {Aspects légaux de la psychiatrie au {Québec}},\n\turl = {https://www.ciussscentreouest.ca/programmes-et-services/sante-mentale-et-dependance/qui-sommes-nous/concepts-legaux-en-sante-mentale-et-dependance/aspects-legaux-de-la-psychiatrie-au-quebec/},\n\tlanguage = {fr},\n\turldate = {2023-08-24},\n\tauthor = {{CIUSSS du Centre-Ouest de l'Île de Montréal}},\n\tmonth = jan,\n\tyear = {2023},\n\tkeywords = {Organisation des services},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2022\n \n \n (5)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Vieillissement et consommation : mieux accompagner les aîné·e·s qui consomment des substances psychoactives en milieu d’hébergement et de soins de longue durée.\n \n \n \n \n\n\n \n universitaire sur les dépendances , I.\n\n\n \n\n\n\n March 2022.\n \n\n\n\n
\n\n\n\n \n \n \"VieillissementPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{institut_universitaire_sur_les_dependances_vieillissement_2022,\n\ttitle = {Vieillissement et consommation : mieux accompagner les aîné·e·s qui consomment des substances psychoactives en milieu d’hébergement et de soins de longue durée},\n\tshorttitle = {Vieillissement et consommation},\n\turl = {https://iud.quebec/fr/evenement/vieillissement-et-consommation-mieux-accompagner-les-ainees-qui-consomment-des-substances-psychoactives-en-milieu},\n\tlanguage = {fr-CA},\n\turldate = {2023-04-14},\n\tauthor = {Institut universitaire sur les dépendances},\n\tmonth = mar,\n\tyear = {2022},\n\tkeywords = {Documents généraux sur les troubles concomitants},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Surveiller, contrôler et traiter : le consentement aux soins à la Commission québécoise d’examen.\n \n \n \n \n\n\n \n Bernheim, E.; Ouellet, G.; Pariseau-Legault, P.; and Sallée, N.\n\n\n \n\n\n\n Santé mentale au Québec, 47(1): 111–128. 2022.\n \n\n\n\n
\n\n\n\n \n \n \"Surveiller,Paper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@article{bernheim_surveiller_2022,\n\ttitle = {Surveiller, contrôler et traiter : le consentement aux soins à la {Commission} québécoise d’examen},\n\tvolume = {47},\n\tissn = {0383-6320, 1708-3923},\n\tshorttitle = {Surveiller, contrôler et traiter},\n\turl = {https://www.erudit.org/en/journals/smq/1900-v1-n1-smq07483/1094147ar/},\n\tdoi = {10.7202/1094147ar},\n\tabstract = {Objectives The right to refuse care for accused persons found        criminally not responsible on account of mental disorder or unfit to stand trial is        recognized and strictly regulated by the legal mechanisms of Quebec civil law, and Canadian        criminal law does not allow them to be treated against their will. Review Boards, which are        responsible for ruling on and periodically re-evaluating their situation, cannot prescribe        treatment, but have the authority, with the consent of the accused, to impose a condition        relating to treatment. The purpose of this ethnographic study is to document the discourse        and practices of the Quebec Review Board in this area.},\n\tlanguage = {fr},\n\tnumber = {1},\n\turldate = {2023-05-16},\n\tjournal = {Santé mentale au Québec},\n\tauthor = {Bernheim, Emmanuelle and Ouellet, Guillaume and Pariseau-Legault, Pierre and Sallée, Nicolas},\n\tyear = {2022},\n\tkeywords = {Organisation des services},\n\tpages = {111--128},\n}\n\n
\n
\n\n\n
\n Objectives The right to refuse care for accused persons found criminally not responsible on account of mental disorder or unfit to stand trial is recognized and strictly regulated by the legal mechanisms of Quebec civil law, and Canadian criminal law does not allow them to be treated against their will. Review Boards, which are responsible for ruling on and periodically re-evaluating their situation, cannot prescribe treatment, but have the authority, with the consent of the accused, to impose a condition relating to treatment. The purpose of this ethnographic study is to document the discourse and practices of the Quebec Review Board in this area.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Grand public: trouble anxiété sociale.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n October 2022.\n \n\n\n\n
\n\n\n\n \n \n \"GrandPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{noauthor_grand_2022,\n\ttitle = {Grand public: trouble anxiété sociale},\n\tshorttitle = {– {Grand} public},\n\turl = {https://tccmontreal.com/grand-public/grand-public-trouble-anxiete-sociale/},\n\tabstract = {Thérapie cognitivo-comportementale du trouble anxiété sociale: manuel d’information destiné à la clientèle (2022) Trouble anxiété sociale outils et questionnaires Échelle d’anxiété sociale de Liebo…},\n\tlanguage = {fr-CA},\n\turldate = {2022-11-29},\n\tjournal = {Thérapie cognitivo-comportementale: guides de pratiques et autres outils},\n\tmonth = oct,\n\tyear = {2022},\n\tkeywords = {Outils d'intervention},\n}\n\n
\n
\n\n\n
\n Thérapie cognitivo-comportementale du trouble anxiété sociale: manuel d’information destiné à la clientèle (2022) Trouble anxiété sociale outils et questionnaires Échelle d’anxiété sociale de Liebo…\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update.\n \n \n \n\n\n \n Fischer, B.; Robinson, T.; Bullen, C.; Curran, V.; Jutras-Aswad, D.; Medina-Mora, M. E.; Pacula, R. L.; Rehm, J.; Room, R.; Brink, W. v. d.; and Hall, W.\n\n\n \n\n\n\n The International Journal on Drug Policy, 99: 103381. January 2022.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{fischer_lower-risk_2022,\n\ttitle = {Lower-{Risk} {Cannabis} {Use} {Guidelines} ({LRCUG}) for reducing health harms from non-medical cannabis use: {A} comprehensive evidence and recommendations update},\n\tvolume = {99},\n\tissn = {1873-4758},\n\tshorttitle = {Lower-{Risk} {Cannabis} {Use} {Guidelines} ({LRCUG}) for reducing health harms from non-medical cannabis use},\n\tdoi = {10.1016/j.drugpo.2021.103381},\n\tabstract = {BACKGROUND: Cannabis use is common, especially among young people, and is associated with risks for various health harms. Some jurisdictions have recently moved to legalization/regulation pursuing public health goals. Evidence-based 'Lower Risk Cannabis Use Guidelines' (LRCUG) and recommendations were previously developed to reduce modifiable risk factors of cannabis-related adverse health outcomes; related evidence has evolved substantially since. We aimed to review new scientific evidence and to develop comprehensively up-to-date LRCUG, including their recommendations, on this evidence basis.\nMETHODS: Targeted searches for literature (since 2016) on main risk factors for cannabis-related adverse health outcomes modifiable by the user-individual were conducted. Topical areas were informed by previous LRCUG content and expanded upon current evidence. Searches preferentially focused on systematic reviews, supplemented by key individual studies. The review results were evidence-graded, topically organized and narratively summarized; recommendations were developed through an iterative scientific expert consensus development process.\nRESULTS: A substantial body of modifiable risk factors for cannabis use-related health harms were identified with varying evidence quality. Twelve substantive recommendation clusters and three precautionary statements were developed. In general, current evidence suggests that individuals can substantially reduce their risk for adverse health outcomes if they delay the onset of cannabis use until after adolescence, avoid the use of high-potency (THC) cannabis products and high-frequency/-intensity of use, and refrain from smoking-routes for administration. While young people are particularly vulnerable to cannabis-related harms, other sub-groups (e.g., pregnant women, drivers, older adults, those with co-morbidities) are advised to exercise particular caution with use-related risks. Legal/regulated cannabis products should be used where possible.\nCONCLUSIONS: Cannabis use can result in adverse health outcomes, mostly among sub-groups with higher-risk use. Reducing the risk factors identified can help to reduce health harms from use. The LRCUG offer one targeted intervention component within a comprehensive public health approach for cannabis use. They require effective audience-tailoring and dissemination, regular updating as new evidence become available, and should be evaluated for their impact.},\n\tlanguage = {eng},\n\tjournal = {The International Journal on Drug Policy},\n\tauthor = {Fischer, Benedikt and Robinson, Tessa and Bullen, Chris and Curran, Valerie and Jutras-Aswad, Didier and Medina-Mora, Maria Elena and Pacula, Rosalie Liccardo and Rehm, Jürgen and Room, Robin and Brink, Wim van den and Hall, Wayne},\n\tmonth = jan,\n\tyear = {2022},\n\tpmid = {34465496},\n\tpages = {103381},\n}\n\n
\n
\n\n\n
\n BACKGROUND: Cannabis use is common, especially among young people, and is associated with risks for various health harms. Some jurisdictions have recently moved to legalization/regulation pursuing public health goals. Evidence-based 'Lower Risk Cannabis Use Guidelines' (LRCUG) and recommendations were previously developed to reduce modifiable risk factors of cannabis-related adverse health outcomes; related evidence has evolved substantially since. We aimed to review new scientific evidence and to develop comprehensively up-to-date LRCUG, including their recommendations, on this evidence basis. METHODS: Targeted searches for literature (since 2016) on main risk factors for cannabis-related adverse health outcomes modifiable by the user-individual were conducted. Topical areas were informed by previous LRCUG content and expanded upon current evidence. Searches preferentially focused on systematic reviews, supplemented by key individual studies. The review results were evidence-graded, topically organized and narratively summarized; recommendations were developed through an iterative scientific expert consensus development process. RESULTS: A substantial body of modifiable risk factors for cannabis use-related health harms were identified with varying evidence quality. Twelve substantive recommendation clusters and three precautionary statements were developed. In general, current evidence suggests that individuals can substantially reduce their risk for adverse health outcomes if they delay the onset of cannabis use until after adolescence, avoid the use of high-potency (THC) cannabis products and high-frequency/-intensity of use, and refrain from smoking-routes for administration. While young people are particularly vulnerable to cannabis-related harms, other sub-groups (e.g., pregnant women, drivers, older adults, those with co-morbidities) are advised to exercise particular caution with use-related risks. Legal/regulated cannabis products should be used where possible. CONCLUSIONS: Cannabis use can result in adverse health outcomes, mostly among sub-groups with higher-risk use. Reducing the risk factors identified can help to reduce health harms from use. The LRCUG offer one targeted intervention component within a comprehensive public health approach for cannabis use. They require effective audience-tailoring and dissemination, regular updating as new evidence become available, and should be evaluated for their impact.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Vitamin Supplements as a Nutritional Strategy against Chronic Alcohol Consumption? An Updated Review.\n \n \n \n\n\n \n Sandoval, C.; Farías, J.; Zamorano, M.; and Herrera, C.\n\n\n \n\n\n\n Antioxidants (Basel, Switzerland), 11(3): 564. March 2022.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{sandoval_vitamin_2022,\n\ttitle = {Vitamin {Supplements} as a {Nutritional} {Strategy} against {Chronic} {Alcohol} {Consumption}? {An} {Updated} {Review}},\n\tvolume = {11},\n\tissn = {2076-3921},\n\tshorttitle = {Vitamin {Supplements} as a {Nutritional} {Strategy} against {Chronic} {Alcohol} {Consumption}?},\n\tdoi = {10.3390/antiox11030564},\n\tabstract = {Several studies have shown that blood vitamin levels are low in alcoholic patients. In effect, alcohol use abuse is considered a chronic disease that promotes the pathogenesis of many fatal diseases, such as cancer and liver cirrhosis. The alcohol effects in the liver can be prevented by antioxidant mechanisms, which induces enzymatic as well as other nonenzymatic pathways. The effectiveness of several antioxidants has been evaluated. However, these studies have been accompanied by uncertainty as mixed results were reported. Thus, the aim of the present review article was to examine the current knowledge on vitamin deficiency and its role in chronic liver disease. Our review found that deficiencies in nutritional vitamins could develop rapidly during chronic liver disease due to diminished hepatic storage and that inadequate vitamins intake and alcohol consumption may interact to deplete vitamin levels. Numerous studies have described that vitamin supplementation could reduce hepatotoxicity. However, further studies with reference to the changes in vitamin status and the nutritional management of chronic liver disease are in demand.},\n\tlanguage = {eng},\n\tnumber = {3},\n\tjournal = {Antioxidants (Basel, Switzerland)},\n\tauthor = {Sandoval, Cristian and Farías, Jorge and Zamorano, Mauricio and Herrera, Christian},\n\tmonth = mar,\n\tyear = {2022},\n\tpmid = {35326214},\n\tpmcid = {PMC8945215},\n\tkeywords = {alcoholic liver disease, vitamin B1, vitamin C, vitamin D, vitamin E},\n\tpages = {564},\n}\n\n
\n
\n\n\n
\n Several studies have shown that blood vitamin levels are low in alcoholic patients. In effect, alcohol use abuse is considered a chronic disease that promotes the pathogenesis of many fatal diseases, such as cancer and liver cirrhosis. The alcohol effects in the liver can be prevented by antioxidant mechanisms, which induces enzymatic as well as other nonenzymatic pathways. The effectiveness of several antioxidants has been evaluated. However, these studies have been accompanied by uncertainty as mixed results were reported. Thus, the aim of the present review article was to examine the current knowledge on vitamin deficiency and its role in chronic liver disease. Our review found that deficiencies in nutritional vitamins could develop rapidly during chronic liver disease due to diminished hepatic storage and that inadequate vitamins intake and alcohol consumption may interact to deplete vitamin levels. Numerous studies have described that vitamin supplementation could reduce hepatotoxicity. However, further studies with reference to the changes in vitamin status and the nutritional management of chronic liver disease are in demand.\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2021\n \n \n (6)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Tableau types de cannabis.\n \n \n \n \n\n\n \n Desaulniers, P.\n\n\n \n\n\n\n 2021.\n \n\n\n\n
\n\n\n\n \n \n \"TableauPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{desaulniers_tableau_2021,\n\ttitle = {Tableau types de cannabis},\n\turl = {https://bibliothequeduchum.ca/projets/tc/documents/Tableau_types_cannabis_CHUM_2021.pdf},\n\tauthor = {Desaulniers, P.},\n\tyear = {2021},\n\tkeywords = {Outils d'intervention},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n La sécurisation culturelle en santé et en services sociaux : Vers des soins et des services culturellement sécurisants pour les Premières Nations et les Inuit.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n Technical Report Ministère de la Santé et des Services Sociaux, 2021.\n \n\n\n\n
\n\n\n\n \n \n \"LaPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@techreport{noauthor_securisation_2021,\n\ttitle = {La sécurisation culturelle en santé et en services sociaux : {Vers} des soins et des services culturellement sécurisants pour les {Premières} {Nations} et les {Inuit}},\n\turl = {https://publications.msss.gouv.qc.ca/msss/fichiers/2020/20-613-02W.pdf},\n\turldate = {2023-02-07},\n\tinstitution = {Ministère de la Santé et des Services Sociaux},\n\tyear = {2021},\n\tkeywords = {Implantation de bonnes pratiques et de services intégrés},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Une image vaut 1000 droits.\n \n \n \n \n\n\n \n Colpron, M.\n\n\n \n\n\n\n 2021.\n \n\n\n\n
\n\n\n\n \n \n \"UnePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@misc{colpron_image_2021,\n\ttitle = {Une image vaut 1000 droits},\n\turl = {https://biblio.cegepba.qc.ca/wp-content/uploads/2021/06/synthese-droit-auteur-images.pdf},\n\tauthor = {Colpron, Mathieu},\n\tyear = {2021},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update.\n \n \n \n \n\n\n \n Fischer, B.; Robinson, T.; Bullen, C.; Curran, V.; Jutras-Aswad, D.; Medina-Mora, M. E.; Pacula, R. L.; Rehm, J.; Room, R.; Brink, W. v. d.; and Hall, W.\n\n\n \n\n\n\n International Journal of Drug Policy,103381. August 2021.\n \n\n\n\n
\n\n\n\n \n \n \"Lower-RiskPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@article{fischer_lower-risk_2021,\n\ttitle = {Lower-{Risk} {Cannabis} {Use} {Guidelines} ({LRCUG}) for reducing health harms from non-medical cannabis use: {A} comprehensive evidence and recommendations update},\n\tissn = {0955-3959},\n\tshorttitle = {Lower-{Risk} {Cannabis} {Use} {Guidelines} ({LRCUG}) for reducing health harms from non-medical cannabis use},\n\turl = {https://www.sciencedirect.com/science/article/pii/S0955395921002863},\n\tdoi = {10.1016/j.drugpo.2021.103381},\n\tabstract = {Background\nCannabis use is common, especially among young people, and is associated with risks for various health harms. Some jurisdictions have recently moved to legalization/regulation pursuing public health goals. Evidence-based ‘Lower Risk Cannabis Use Guidelines’ (LRCUG) and recommendations were previously developed to reduce modifiable risk factors of cannabis-related adverse health outcomes; related evidence has evolved substantially since. We aimed to review new scientific evidence and to develop comprehensively up-to-date LRCUG, including their recommendations, on this evidence basis.\nMethods\nTargeted searches for literature (since 2016) on main risk factors for cannabis-related adverse health outcomes modifiable by the user-individual were conducted. Topical areas were informed by previous LRCUG content and expanded upon current evidence. Searches preferentially focused on systematic reviews, supplemented by key individual studies. The review results were evidence-graded, topically organized and narratively summarized; recommendations were developed through an iterative scientific expert consensus development process.\nResults\nA substantial body of modifiable risk factors for cannabis use-related health harms were identified with varying evidence quality. Twelve substantive recommendation clusters and three precautionary statements were developed. In general, current evidence suggests that individuals can substantially reduce their risk for adverse health outcomes if they delay the onset of cannabis use until after adolescence, avoid the use of high-potency (THC) cannabis products and high-frequency/-intensity of use, and refrain from smoking-routes for administration. While young people are particularly vulnerable to cannabis-related harms, other sub-groups (e.g., pregnant women, drivers, older adults, those with co-morbidities) are advised to exercise particular caution with use-related risks. Legal/regulated cannabis products should be used where possible.\nConclusions\nCannabis use can result in adverse health outcomes, mostly among sub-groups with higher-risk use. Reducing the risk factors identified can help to reduce health harms from use. The LRCUG offer one targeted intervention component within a comprehensive public health approach for cannabis use. They require effective audience-tailoring and dissemination, regular updating as new evidence become available, and should be evaluated for their impact.},\n\tlanguage = {en},\n\turldate = {2021-08-31},\n\tjournal = {International Journal of Drug Policy},\n\tauthor = {Fischer, Benedikt and Robinson, Tessa and Bullen, Chris and Curran, Valerie and Jutras-Aswad, Didier and Medina-Mora, Maria Elena and Pacula, Rosalie Liccardo and Rehm, Jürgen and Room, Robin and Brink, Wim van den and Hall, Wayne},\n\tmonth = aug,\n\tyear = {2021},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n\tpages = {103381},\n}\n\n
\n
\n\n\n
\n Background Cannabis use is common, especially among young people, and is associated with risks for various health harms. Some jurisdictions have recently moved to legalization/regulation pursuing public health goals. Evidence-based ‘Lower Risk Cannabis Use Guidelines’ (LRCUG) and recommendations were previously developed to reduce modifiable risk factors of cannabis-related adverse health outcomes; related evidence has evolved substantially since. We aimed to review new scientific evidence and to develop comprehensively up-to-date LRCUG, including their recommendations, on this evidence basis. Methods Targeted searches for literature (since 2016) on main risk factors for cannabis-related adverse health outcomes modifiable by the user-individual were conducted. Topical areas were informed by previous LRCUG content and expanded upon current evidence. Searches preferentially focused on systematic reviews, supplemented by key individual studies. The review results were evidence-graded, topically organized and narratively summarized; recommendations were developed through an iterative scientific expert consensus development process. Results A substantial body of modifiable risk factors for cannabis use-related health harms were identified with varying evidence quality. Twelve substantive recommendation clusters and three precautionary statements were developed. In general, current evidence suggests that individuals can substantially reduce their risk for adverse health outcomes if they delay the onset of cannabis use until after adolescence, avoid the use of high-potency (THC) cannabis products and high-frequency/-intensity of use, and refrain from smoking-routes for administration. While young people are particularly vulnerable to cannabis-related harms, other sub-groups (e.g., pregnant women, drivers, older adults, those with co-morbidities) are advised to exercise particular caution with use-related risks. Legal/regulated cannabis products should be used where possible. Conclusions Cannabis use can result in adverse health outcomes, mostly among sub-groups with higher-risk use. Reducing the risk factors identified can help to reduce health harms from use. The LRCUG offer one targeted intervention component within a comprehensive public health approach for cannabis use. They require effective audience-tailoring and dissemination, regular updating as new evidence become available, and should be evaluated for their impact.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Trouble lié à l'usage d'opioïdes (TUO).\n \n \n \n \n\n\n \n INESSS\n\n\n \n\n\n\n 2021.\n \n\n\n\n
\n\n\n\n \n \n \"TroublePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{inesss_trouble_2021,\n\ttitle = {Trouble lié à l'usage d'opioïdes ({TUO})},\n\turl = {https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/GUO_TUO_FR.pdf},\n\turldate = {2021-11-23},\n\tauthor = {{INESSS}},\n\tyear = {2021},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Sevrage d'alcool et prévention des rechutes.\n \n \n \n \n\n\n \n INESSS\n\n\n \n\n\n\n 2021.\n \n\n\n\n
\n\n\n\n \n \n \"SevragePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{inesss_sevrage_2021,\n\ttitle = {Sevrage d'alcool et prévention des rechutes},\n\turl = {https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Usage_optimal/INESSS_GUO_Sevrage_rechute_FR.pdf},\n\turldate = {2021-11-23},\n\tauthor = {{INESSS}},\n\tyear = {2021},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2020\n \n \n (18)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Recommandations canadiennes pour l'usage du cannabis à moindre risque.\n \n \n \n \n\n\n \n Santé Canada\n\n\n \n\n\n\n January 2020.\n Last Modified: 2020-01-22\n\n\n\n
\n\n\n\n \n \n \"RecommandationsPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{sante_canada_recommandations_2020,\n\ttitle = {Recommandations canadiennes pour l'usage du cannabis à moindre risque},\n\turl = {https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/ressources/recommendations-usage-cannabis-moindre-risque.html},\n\tabstract = {Les lignes directrices canadiennes (RUCMR) fournissent des recommandations fondées sur des données scientifiques afin de permettre aux gens de réduire les risques pour la santé associés à la consommation de cannabis.},\n\tlanguage = {fra},\n\turldate = {2021-10-19},\n\tauthor = {{Santé Canada}},\n\tmonth = jan,\n\tyear = {2020},\n\tnote = {Last Modified: 2020-01-22},\n\tkeywords = {Outils d'intervention},\n}\n\n
\n
\n\n\n
\n Les lignes directrices canadiennes (RUCMR) fournissent des recommandations fondées sur des données scientifiques afin de permettre aux gens de réduire les risques pour la santé associés à la consommation de cannabis.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Le cadre thérapeutique en contexte de pandémie : vers un nouvel équilibre.\n \n \n \n \n\n\n \n Magny, A.\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"LePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n 
@misc{magny_cadre_2020,\n\ttitle = {Le cadre thérapeutique en contexte de pandémie : vers un nouvel équilibre},\n\turl = {https://www.ordrepsy.qc.ca/-/le-cadre-therapeutique-en-contexte-de-pandemie-vers-un-nouvel-equilibre/1.5},\n\turldate = {2022-05-03},\n\tjournal = {Ordre des Psychologues du Québec},\n\tauthor = {Magny, André-Anne},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge psychosociale, \\_COVID-19},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Entretenir ma vitalité d'aidant: guide pour prévenir la fatigue de compassion et la détresse professionnelle.\n \n \n \n\n\n \n Brillon, P.\n\n\n \n\n\n\n Les Éditions de l'Homme, Montréal, Québec, 2020.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@book{brillon_entretenir_2020,\n\taddress = {Montréal, Québec},\n\ttitle = {Entretenir ma vitalité d'aidant: guide pour prévenir la fatigue de compassion et la détresse professionnelle},\n\tisbn = {978-2-7619-5271-2 978-2-7619-5272-9},\n\tshorttitle = {Entretenir ma vitalité d'aidant},\n\tabstract = {Vous êtes psychologue, travailleur social, médecin, thérapeute, professionnel de la santé mentale et physique, travailleur humanitaire, ou premier répondant. Vous aidez, vous soutenez, vous conseillez, vous êtes présent en situation de crise, lorsque tout semble s'écrouler. Vous avez choisi ce métier par vocation, mais, actuellement, vous le trouvez plus lourd à porter. Vous vous sentez parfois abattu, épuisé ou impuissant face à toute cette souffrance. Alors ce livre est pour vous! [éditeur]},\n\tpublisher = {Les Éditions de l'Homme},\n\tauthor = {Brillon, Pascale},\n\tyear = {2020},\n\tkeywords = {Outils d'intervention},\n}\n\n
\n
\n\n\n
\n Vous êtes psychologue, travailleur social, médecin, thérapeute, professionnel de la santé mentale et physique, travailleur humanitaire, ou premier répondant. Vous aidez, vous soutenez, vous conseillez, vous êtes présent en situation de crise, lorsque tout semble s'écrouler. Vous avez choisi ce métier par vocation, mais, actuellement, vous le trouvez plus lourd à porter. Vous vous sentez parfois abattu, épuisé ou impuissant face à toute cette souffrance. Alors ce livre est pour vous! [éditeur]\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Cannabis, grossesse et allaitement.\n \n \n \n \n\n\n \n CHU Sainte-Justine - Centre de promotion de la santé\n\n\n \n\n\n\n Technical Report 2020.\n \n\n\n\n
\n\n\n\n \n \n \"Cannabis,Paper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@techreport{chu_sainte-justine_-_centre_de_promotion_de_la_sante_cannabis_2020,\n\ttitle = {Cannabis, grossesse et allaitement},\n\turl = {https://www.chusj.org/getmedia/0c334882-9b53-49bf-8d10-a2229a0b398e/Fiche-thematique-Cannabis-Gossesse-Allaitement.pdf.aspx?ext=.pdf},\n\turldate = {2023-01-24},\n\tauthor = {{CHU Sainte-Justine - Centre de promotion de la santé}},\n\tyear = {2020},\n\tkeywords = {Outils d'intervention},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n La pharmacothérapie de remplacement des substances psychoactives dans le contexte de pandémie de COVID-19 au Québec : guide clinique à l'intention des prescripteurs.\n \n \n \n \n\n\n \n Goyer, M.; Hudon, K; Plessis-Bélair, M.; and Ferguson, Y\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"LaPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 5 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n 
@misc{goyer_pharmacotherapie_2020,\n\ttitle = {La pharmacothérapie de remplacement des substances psychoactives dans le contexte de pandémie de {COVID}-19 au {Québec} : guide clinique à l'intention des prescripteurs},\n\turl = {https://www.bibliothequeduchum.ca/projets/tc/documents/Guide%20clinique%20Pharmacothe%CC%81rapie%20COVID_9-6-2020.pdf},\n\turldate = {2020-06-29},\n\tpublisher = {Institut universitaire sur les dépendances},\n\tauthor = {Goyer, ME and Hudon, K and Plessis-Bélair, MC and Ferguson, Y},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale, \\_COVID-19},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Medications and other clinical approaches to support physical distancing for people who use substances during the COVID-19 pandemic.\n \n \n \n \n\n\n \n Brar, R; Bruneau, J; Butt, P; Goyer, M.; Lim, R; Poulin, G; Sereda, A; Robinson, S; and Wood, E\n\n\n \n\n\n\n June 2020.\n \n\n\n\n
\n\n\n\n \n \n \"MedicationsPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n 
@misc{brar_medications_2020,\n\ttitle = {Medications and other clinical approaches to support physical distancing for people who use substances during the {COVID}-19 pandemic},\n\turl = {https://www.crismquebecatlantic.ca/fr/medications-and-other-clinical-approaches-to-support-physical-distancing-for-people-who-use-substances-during-the-covid-19-pandemic/},\n\tlanguage = {Anglais},\n\turldate = {2020-06-29},\n\tpublisher = {Canadian Research Initiative in Substance Misuse},\n\tauthor = {Brar, R and Bruneau, J and Butt, P and Goyer, ME and Lim, R and Poulin, G and Sereda, A and Robinson, S and Wood, E},\n\tmonth = jun,\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale, \\_COVID-19},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Médication et autres approches pour soutenir la distanciation physique des personnes utilisatrices de substances : guide pratique national.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"MédicationPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n 
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_medication_2020,\n\ttitle = {Médication et autres approches pour soutenir la distanciation physique des personnes utilisatrices de substances : guide pratique national},\n\turl = {https://crism.ca/wp-content/uploads/2020/08/Me%CC%81dication-et-autres-approches-pour-soutenir-la-distanciation-physique-des-personnes-utilisatrices-de-substances-31072020.pdf},\n\turldate = {2020-09-28},\n\tauthor = {{Initiative canadienne de recherche en abus de substance}},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale, \\_COVID-19},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Stratégies pour réduire la transmission du SRASCoV-2 dans les centres de réadaptation en dépendance et d’hébergement : guide pratique national.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"StratégiesPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n 
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_strategies_2020,\n\ttitle = {Stratégies pour réduire la transmission du {SRASCoV}-2 dans les centres de réadaptation en dépendance et d’hébergement : guide pratique national},\n\turl = {https://crism.ca/wp-content/uploads/2020/09/Strat%C3%A9gies-pour-r%C3%A9duire-la-transmission-du-SRAS-CoV-2-dans-les-centres-de-r%C3%A9adaptation-en-d%C3%A9pendance-et-d%E2%80%99h%C3%A9bergement-20072020.pdf},\n\turldate = {2020-09-28},\n\tauthor = {{Initiative canadienne de recherche en abus de substance}},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale, \\_COVID-19},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Sécurité des travailleurs en prévention et réduction des risques durant la pandémie de la COVID‑19 : guide pratique national.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"SécuritéPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 5 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n 
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_securite_2020,\n\ttitle = {Sécurité des travailleurs en prévention et réduction des risques durant la pandémie de la {COVID}‑19 : guide pratique national},\n\turl = {https://crism.ca/wp-content/uploads/2020/09/S%C3%A9curit%C3%A9-des-travailleurs-en-pr%C3%A9vention-et-r%C3%A9duction-des-risques-durant-la-pand%C3%A9mie-de-la-COVID-19-31072020.pdf},\n\turldate = {2020-09-28},\n\tauthor = {{Initiative canadienne de recherche en abus de substance}},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale, \\_COVID-19},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Soutenir les personnes utilisatrices de substances dans un milieu de soins de courte durée pendant la pandémie de la COVID‑19 : guide pratique national.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"SoutenirPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n 
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_soutenir_2020,\n\ttitle = {Soutenir les personnes utilisatrices de substances dans un milieu de soins de courte durée pendant la pandémie de la {COVID}‑19 : guide pratique national},\n\turl = {https://crism.ca/wp-content/uploads/2020/08/Soutenir-les-PUS-dans-un-milieu-de-soins-de-courte-dur%C3%A9e-31072020.pdf},\n\turldate = {2020-09-28},\n\tauthor = {{Initiative canadienne de recherche en abus de substance}},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale, \\_COVID-19},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Soutenir les personnes utilisatrices de substances dans les centres d’accueil pendant la pandémie de la COVID‑19 : guide pratique national.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"SoutenirPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n 
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_soutenir_2020-1,\n\ttitle = {Soutenir les personnes utilisatrices de substances dans les centres d’accueil pendant la pandémie de la {COVID}‑19 : guide pratique national},\n\turl = {https://crism.ca/wp-content/uploads/2020/08/Soutenir-les-personnes-utilisatrices-de-substances-dans-les-centres-d%E2%80%99accueil-pendant-la-pand%C3%A9mie-de-la-COVID-19-14072020.pdf},\n\turldate = {2020-09-28},\n\tauthor = {{Initiative canadienne de recherche en abus de substance}},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale, \\_COVID-19},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Repères pour l'intervention téléphonique.\n \n \n \n \n\n\n \n CIUSSS Saguenay-Lac-St-Jean; and Centre de recherche appliquée en intervention psychosociale\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"RepèresPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 5 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n 
@misc{ciusss_saguenay-lac-st-jean_reperes_2020,\n\ttitle = {Repères pour l'intervention téléphonique},\n\turl = {https://ccsmtlpro.ca/fileadmin/ciusss_ceim/ZoneProfessionnelle/DocumentationSujets/SanteMentale/BoiteOutilsIntervenantsDependance/InterventionPsychosociale/Intervenants/ReperesInterventionTelephonique.pdf},\n\turldate = {2020-10-05},\n\tauthor = {{CIUSSS Saguenay-Lac-St-Jean} and {Centre de recherche appliquée en intervention psychosociale}},\n\tyear = {2020},\n\tkeywords = {Implantation de bonnes pratiques et de services intégrés, \\_COVID-19},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Lettre ouverte - Déconfinement : pas pour tout le monde.\n \n \n \n \n\n\n \n Association des intervenants en dépendance du Québec\n\n\n \n\n\n\n May 2020.\n Section: Actualités\n\n\n\n
\n\n\n\n \n \n \"LettrePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{association_des_intervenants_en_dependance_du_quebec_lettre_2020,\n\ttitle = {Lettre ouverte - {Déconfinement} : pas pour tout le monde},\n\tshorttitle = {Lettre ouverte - {Déconfinement}},\n\turl = {https://aidq.org/lettre-ouverte-deconfinement-pas-pour-tout-le-monde},\n\tabstract = {Le déconfinement s’amorce au Québec. Malheureusement, pour plusieurs, le confinement continuera. Le confinement derrière le mur du silence. Derrière ce mur, se trouvera des personnes particulièrement fragilisées par la crise : celles vivant avec la dépendance (alcool, drogues, médicaments, jeux de hasard et d’argent ou hyperconnectivité).  En temps de crise, l’usage de substances et la …},\n\tlanguage = {fr},\n\turldate = {2020-06-29},\n\tauthor = {{Association des intervenants en dépendance du Québec}},\n\tmonth = may,\n\tyear = {2020},\n\tnote = {Section: Actualités},\n\tkeywords = {\\_COVID-19},\n}\n\n
\n
\n\n\n
\n Le déconfinement s’amorce au Québec. Malheureusement, pour plusieurs, le confinement continuera. Le confinement derrière le mur du silence. Derrière ce mur, se trouvera des personnes particulièrement fragilisées par la crise : celles vivant avec la dépendance (alcool, drogues, médicaments, jeux de hasard et d’argent ou hyperconnectivité).  En temps de crise, l’usage de substances et la …\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n Journal of Addiction Medicine, 14(3S): 1–72. June 2020.\n \n\n\n\n
\n\n\n\n \n \n \"ThePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@article{noauthor_asam_2020,\n\ttitle = {The {ASAM} {Clinical} {Practice} {Guideline} on {Alcohol} {Withdrawal} {Management}},\n\tvolume = {14},\n\tissn = {1932-0620},\n\turl = {https://journals.lww.com/journaladdictionmedicine/Fulltext/2020/06001/The_ASAM_Clinical_Practice_Guideline_on_Alcohol.1.aspx},\n\tdoi = {10.1097/ADM.0000000000000668},\n\tlanguage = {en-US},\n\tnumber = {3S},\n\turldate = {2020-09-29},\n\tjournal = {Journal of Addiction Medicine},\n\tmonth = jun,\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n\tpages = {1--72},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.\n \n \n \n\n\n \n Wong, J.; Saver, B.; Scanlan, J. M.; Gianutsos, L. P.; Bhakta, Y.; Walsh, J.; Plawman, A.; Sapienza, D.; and Rudolf, V.\n\n\n \n\n\n\n Journal of Addiction Medicine, 14(3S Suppl 1): 1–72. June 2020.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{wong_asam_2020,\n\ttitle = {The {ASAM} {Clinical} {Practice} {Guideline} on {Alcohol} {Withdrawal} {Management}},\n\tvolume = {14},\n\tissn = {1935-3227},\n\tdoi = {10.1097/ADM.0000000000000668},\n\tlanguage = {eng},\n\tnumber = {3S Suppl 1},\n\tjournal = {Journal of Addiction Medicine},\n\tauthor = {Wong, Jacqueline and Saver, Barry and Scanlan, James M. and Gianutsos, Louis Paul and Bhakta, Yachana and Walsh, James and Plawman, Abigail and Sapienza, David and Rudolf, Vania},\n\tmonth = jun,\n\tyear = {2020},\n\tpmid = {32511109},\n\tpages = {1--72},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Télémédecine pour le traitement des troubles liés à l'usage de substances psychoactives : guide pratique national.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"TélémédecinePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_telemedecine_2020,\n\ttitle = {Télémédecine pour le traitement des troubles liés à l'usage de substances psychoactives : guide pratique national},\n\turl = {https://crism.ca/wp-content/uploads/2020/08/COVID19-LDPN-Telemedecine-01072020.pdf},\n\turldate = {2020-09-28},\n\tauthor = {{Initiative canadienne de recherche en abus de substance}},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Portrait des troubles liés aux substances psychoactives : troubles mentaux concomitants et utilisation des services médicaux en santé mentale.\n \n \n \n \n\n\n \n Huynh, C.; Rochette, L.; Pelletier, E.; Jutras-Aswad, D.; Fleury, M.; Kisely, S.; and Lesage, A.\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"PortraitPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 6 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{huynh_portrait_2020,\n\ttitle = {Portrait des troubles liés aux substances psychoactives : troubles mentaux concomitants et utilisation des services médicaux en santé mentale},\n\tshorttitle = {Portrait des troubles liés aux substances psychoactives},\n\turl = {https://www.inspq.qc.ca/publications/2663},\n\tabstract = {Chez certaines personnes, la consommation excessive ou chronique de substances psychoactives peut mener à l’émergence de troubles liés aux substances (TLS). Il est ici question de la consommation d’alcool, de cannabis, des drogues déclarées illicites ou de médicaments ayant un effet sur le système nerveux central. La proportion de troubles mentaux en 2016-2017 est environ trois fois plus élevée dans la population ayant un trouble lié aux substances psychoactives (TLS) que dans celle qui n’a jamais été diagnostiquée avec un tel trouble depuis 2001 (31 \\% contre 11 \\%). Dans le groupe de personnes ayant un TLS, les troubles anxieux constituent la catégorie la plus diagnostiquée (13 \\%), suivis des troubles dépressifs (8 \\%) et de la schizophrénie (6 \\%). Parmi les personnes diagnostiquées d’un trouble lié à l’alcool ou à une drogue, 63 \\% n’ont pas eu recours à des services médicaux en santé mentale ou en dépendance.},\n\tlanguage = {fr},\n\turldate = {2020-06-29},\n\tpublisher = {Institut national de santé publique du Québec},\n\tauthor = {Huynh, Christophe and Rochette, Louis and Pelletier, Eric and Jutras-Aswad, Didier and Fleury, Marie-Josée and Kisely, Steve and Lesage, Alain},\n\tyear = {2020},\n\tkeywords = {Documents généraux sur les troubles concomitants},\n}\n\n
\n
\n\n\n
\n Chez certaines personnes, la consommation excessive ou chronique de substances psychoactives peut mener à l’émergence de troubles liés aux substances (TLS). Il est ici question de la consommation d’alcool, de cannabis, des drogues déclarées illicites ou de médicaments ayant un effet sur le système nerveux central. La proportion de troubles mentaux en 2016-2017 est environ trois fois plus élevée dans la population ayant un trouble lié aux substances psychoactives (TLS) que dans celle qui n’a jamais été diagnostiquée avec un tel trouble depuis 2001 (31 % contre 11 %). Dans le groupe de personnes ayant un TLS, les troubles anxieux constituent la catégorie la plus diagnostiquée (13 %), suivis des troubles dépressifs (8 %) et de la schizophrénie (6 %). Parmi les personnes diagnostiquées d’un trouble lié à l’alcool ou à une drogue, 63 % n’ont pas eu recours à des services médicaux en santé mentale ou en dépendance.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Le traitement du trouble lié à l'utilisation d'opioïdes (TUO) : lignes directrices.\n \n \n \n \n\n\n \n Collège des médecins du Québec; Ordre des infirmières et infirmiers du Québec; and Ordre des pharmaciens du Québec\n\n\n \n\n\n\n March 2020.\n \n\n\n\n
\n\n\n\n \n \n \"LePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 12 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{college_des_medecins_du_quebec_traitement_2020,\n\ttitle = {Le traitement du trouble lié à l'utilisation d'opioïdes ({TUO}) : lignes directrices},\n\turl = {http://www.cmq.org/publications-pdf/p-1-2020-03-20-fr-le-traitement-du-trouble-lie-a-l-utilisation-d-opioides-tuo.pdf},\n\tlanguage = {fr},\n\turldate = {2020-05-06},\n\tauthor = {{Collège des médecins du Québec} and {Ordre des infirmières et infirmiers du Québec} and {Ordre des pharmaciens du Québec}},\n\tmonth = mar,\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2019\n \n \n (10)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder.\n \n \n \n \n\n\n \n Reus, V. I.; Fochtmann, L. J.; Bukstein, O.; Eyler, A. E.; Hilty, D. M.; Horvitz-Lennon, M.; Mahoney, J.; Pasic, J.; Weaver, M.; Wills, C. D.; McIntyre, J.; Kidd, J.; Yager, J.; and Hong, S.\n\n\n \n\n\n\n Focus (American Psychiatric Publishing), 17(2): 158–162. April 2019.\n \n\n\n\n
\n\n\n\n \n \n \"ThePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@article{reus_american_2019,\n\ttitle = {The {American} {Psychiatric} {Association} {Practice} {Guideline} for the {Pharmacological} {Treatment} of {Patients} {With} {Alcohol} {Use} {Disorder}},\n\tvolume = {17},\n\tissn = {1541-4094},\n\turl = {https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9781615371969},\n\tdoi = {10.1176/appi.focus.17205},\n\tabstract = {(Reprinted with permission from Am J Psychiatry 2018; 175:86-90).},\n\tlanguage = {eng},\n\tnumber = {2},\n\tjournal = {Focus (American Psychiatric Publishing)},\n\tauthor = {Reus, Victor I. and Fochtmann, Laura J. and Bukstein, Oscar and Eyler, A. Evan and Hilty, Donald M. and Horvitz-Lennon, Marcela and Mahoney, Jane and Pasic, Jagoda and Weaver, Michael and Wills, Cheryl D. and McIntyre, Jack and Kidd, Jeremy and Yager, Joel and Hong, Seung-Hee},\n\tmonth = apr,\n\tyear = {2019},\n\tpmid = {32021585},\n\tpmcid = {PMC6527005},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n\tpages = {158--162},\n}\n\n
\n
\n\n\n
\n (Reprinted with permission from Am J Psychiatry 2018; 175:86-90).\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Pharmacotherapies for cannabis dependence.\n \n \n \n\n\n \n Nielsen, S.; Gowing, L.; Sabioni, P.; and Le Foll, B.\n\n\n \n\n\n\n The Cochrane Database of Systematic Reviews, 1: CD008940. January 2019.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@article{nielsen_pharmacotherapies_2019,\n\ttitle = {Pharmacotherapies for cannabis dependence},\n\tvolume = {1},\n\tissn = {1469-493X},\n\tdoi = {10.1002/14651858.CD008940.pub3},\n\tabstract = {BACKGROUND: Globally, cannabis use is prevalent and widespread. There are currently no pharmacotherapies approved for treatment of cannabis use disorders.This is an update of a Cochrane Review first published in the Cochrane Library in Issue 12, 2014.\nOBJECTIVES: To assess the effectiveness and safety of pharmacotherapies as compared with each other, placebo or no pharmacotherapy (supportive care) for reducing symptoms of cannabis withdrawal and promoting cessation or reduction of cannabis use.\nSEARCH METHODS: We updated our searches of the following databases to March 2018: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO and Web of Science.\nSELECTION CRITERIA: Randomised controlled trials (RCTs) and quasi-RCTs involving the use of medications to treat cannabis withdrawal or to promote cessation or reduction of cannabis use, or both, in comparison with other medications, placebo or no medication (supportive care) in people diagnosed as cannabis dependent or who were likely to be dependent.\nDATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane.\nMAIN RESULTS: We included 21 RCTs involving 1755 participants: 18 studies recruited adults (mean age 22 to 41 years); three studies targeted young people (mean age 20 years). Most (75\\%) participants were male. The studies were at low risk of performance, detection and selective outcome reporting bias. One study was at risk of selection bias, and three studies were at risk of attrition bias.All studies involved comparison of active medication and placebo. The medications were diverse, as were the outcomes reported, which limited the extent of analysis.Abstinence at end of treatment was no more likely with Δ9-tetrahydrocannabinol (THC) preparations than with placebo (risk ratio (RR) 0.98, 95\\% confidence interval (CI) 0.64 to 1.52; 305 participants; 3 studies; moderate-quality evidence). For selective serotonin reuptake inhibitor (SSRI) antidepressants, mixed action antidepressants, anticonvulsants and mood stabilisers, buspirone and N-acetylcysteine, there was no difference in the likelihood of abstinence at end of treatment compared to placebo (low- to very low-quality evidence).There was qualitative evidence of reduced intensity of withdrawal symptoms with THC preparations compared to placebo. For other pharmacotherapies, this outcome was either not examined, or no significant differences was reported.Adverse effects were no more likely with THC preparations (RR 1.02, 95\\% CI 0.89 to 1.17; 318 participants; 3 studies) or N-acetylcysteine (RR 0.94, 95\\% CI 0.71 to 1.23; 418 participants; 2 studies) compared to placebo (moderate-quality evidence). For SSRI antidepressants, mixed action antidepressants, buspirone and N-acetylcysteine, there was no difference in adverse effects compared to placebo (low- to very low-quality evidence).There was no difference in the likelihood of withdrawal from treatment due to adverse effects with THC preparations, SSRIs antidepressants, mixed action antidepressants, anticonvulsants and mood stabilisers, buspirone and N-acetylcysteine compared to placebo (low- to very low-quality evidence).There was no difference in the likelihood of treatment completion with THC preparations, SSRI antidepressants, mixed action antidepressants and buspirone compared to placebo (low- to very low-quality evidence) or with N-acetylcysteine compared to placebo (RR 1.06, 95\\% CI 0.93 to 1.21; 418 participants; 2 studies; moderate-quality evidence). Anticonvulsants and mood stabilisers appeared to reduce the likelihood of treatment completion (RR 0.66, 95\\% CI 0.47 to 0.92; 141 participants; 3 studies; low-quality evidence).Available evidence on gabapentin (anticonvulsant), oxytocin (neuropeptide) and atomoxetine was insufficient for estimates of effectiveness.\nAUTHORS' CONCLUSIONS: There is incomplete evidence for all of the pharmacotherapies investigated, and for many outcomes the quality of the evidence was low or very low. Findings indicate that SSRI antidepressants, mixed action antidepressants, bupropion, buspirone and atomoxetine are probably of little value in the treatment of cannabis dependence. Given the limited evidence of efficacy, THC preparations should be considered still experimental, with some positive effects on withdrawal symptoms and craving. The evidence base for the anticonvulsant gabapentin, oxytocin, and N-acetylcysteine is weak, but these medications are also worth further investigation.},\n\tlanguage = {eng},\n\tjournal = {The Cochrane Database of Systematic Reviews},\n\tauthor = {Nielsen, Suzanne and Gowing, Linda and Sabioni, Pamela and Le Foll, Bernard},\n\tmonth = jan,\n\tyear = {2019},\n\tpmid = {30687936},\n\tpmcid = {PMC6360924},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n\tpages = {CD008940},\n}\n\n
\n
\n\n\n
\n BACKGROUND: Globally, cannabis use is prevalent and widespread. There are currently no pharmacotherapies approved for treatment of cannabis use disorders.This is an update of a Cochrane Review first published in the Cochrane Library in Issue 12, 2014. OBJECTIVES: To assess the effectiveness and safety of pharmacotherapies as compared with each other, placebo or no pharmacotherapy (supportive care) for reducing symptoms of cannabis withdrawal and promoting cessation or reduction of cannabis use. SEARCH METHODS: We updated our searches of the following databases to March 2018: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO and Web of Science. SELECTION CRITERIA: Randomised controlled trials (RCTs) and quasi-RCTs involving the use of medications to treat cannabis withdrawal or to promote cessation or reduction of cannabis use, or both, in comparison with other medications, placebo or no medication (supportive care) in people diagnosed as cannabis dependent or who were likely to be dependent. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included 21 RCTs involving 1755 participants: 18 studies recruited adults (mean age 22 to 41 years); three studies targeted young people (mean age 20 years). Most (75%) participants were male. The studies were at low risk of performance, detection and selective outcome reporting bias. One study was at risk of selection bias, and three studies were at risk of attrition bias.All studies involved comparison of active medication and placebo. The medications were diverse, as were the outcomes reported, which limited the extent of analysis.Abstinence at end of treatment was no more likely with Δ9-tetrahydrocannabinol (THC) preparations than with placebo (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.64 to 1.52; 305 participants; 3 studies; moderate-quality evidence). For selective serotonin reuptake inhibitor (SSRI) antidepressants, mixed action antidepressants, anticonvulsants and mood stabilisers, buspirone and N-acetylcysteine, there was no difference in the likelihood of abstinence at end of treatment compared to placebo (low- to very low-quality evidence).There was qualitative evidence of reduced intensity of withdrawal symptoms with THC preparations compared to placebo. For other pharmacotherapies, this outcome was either not examined, or no significant differences was reported.Adverse effects were no more likely with THC preparations (RR 1.02, 95% CI 0.89 to 1.17; 318 participants; 3 studies) or N-acetylcysteine (RR 0.94, 95% CI 0.71 to 1.23; 418 participants; 2 studies) compared to placebo (moderate-quality evidence). For SSRI antidepressants, mixed action antidepressants, buspirone and N-acetylcysteine, there was no difference in adverse effects compared to placebo (low- to very low-quality evidence).There was no difference in the likelihood of withdrawal from treatment due to adverse effects with THC preparations, SSRIs antidepressants, mixed action antidepressants, anticonvulsants and mood stabilisers, buspirone and N-acetylcysteine compared to placebo (low- to very low-quality evidence).There was no difference in the likelihood of treatment completion with THC preparations, SSRI antidepressants, mixed action antidepressants and buspirone compared to placebo (low- to very low-quality evidence) or with N-acetylcysteine compared to placebo (RR 1.06, 95% CI 0.93 to 1.21; 418 participants; 2 studies; moderate-quality evidence). Anticonvulsants and mood stabilisers appeared to reduce the likelihood of treatment completion (RR 0.66, 95% CI 0.47 to 0.92; 141 participants; 3 studies; low-quality evidence).Available evidence on gabapentin (anticonvulsant), oxytocin (neuropeptide) and atomoxetine was insufficient for estimates of effectiveness. AUTHORS' CONCLUSIONS: There is incomplete evidence for all of the pharmacotherapies investigated, and for many outcomes the quality of the evidence was low or very low. Findings indicate that SSRI antidepressants, mixed action antidepressants, bupropion, buspirone and atomoxetine are probably of little value in the treatment of cannabis dependence. Given the limited evidence of efficacy, THC preparations should be considered still experimental, with some positive effects on withdrawal symptoms and craving. The evidence base for the anticonvulsant gabapentin, oxytocin, and N-acetylcysteine is weak, but these medications are also worth further investigation.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Lignes directrices sur le trouble lié à l'utilisation de l'alcool chez les personnes âgées.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n November 2019.\n \n\n\n\n
\n\n\n\n \n \n \"LignesPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{noauthor_lignes_2019,\n\ttitle = {Lignes directrices sur le trouble lié à l'utilisation de l'alcool chez les personnes âgées},\n\turl = {https://ccsmh.ca/consommation-de-substances-et-dependance/alcool/?lang=fr},\n\tlanguage = {fr-FR},\n\turldate = {2023-03-27},\n\tjournal = {La coalition canadienne pour la santé mentale des personnes âgées},\n\tmonth = nov,\n\tyear = {2019},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Guide d'intervention : Consentement aux soins.\n \n \n \n \n\n\n \n intégré de santé et de services sociaux de l'Outaouais , C.\n\n\n \n\n\n\n 2019.\n \n\n\n\n
\n\n\n\n \n \n \"GuidePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@book{centre_integre_de_sante_et_de_services_sociaux_de_loutaouais_guide_2019,\n\ttitle = {Guide d'intervention : {Consentement} aux soins},\n\tisbn = {ISBN 978-2-550-83652-0},\n\turl = {https://numerique.banq.qc.ca/patrimoine/details/52327/3660036},\n\tlanguage = {fr},\n\turldate = {2022-11-17},\n\tauthor = {Centre intégré de santé et de services sociaux de l'Outaouais},\n\tyear = {2019},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Guide de pratique pour la thérapie des schémas.\n \n \n \n \n\n\n \n Gauthier, C.; Chaloult, G.; Goulet, J.; and Ngô, T.\n\n\n \n\n\n\n Technical Report 2019.\n \n\n\n\n
\n\n\n\n \n \n \"GuidePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@techreport{gauthier_guide_2019,\n\ttitle = {Guide de pratique pour la thérapie des schémas},\n\turl = {https://tccmontreal.files.wordpress.com/2019/11/guide-schema-final-1.pdf},\n\turldate = {2022-04-19},\n\tauthor = {Gauthier, C. and Chaloult, G. and Goulet, J. and Ngô, T.L.},\n\tyear = {2019},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Formation ENA : Optimisation de la pratique de counseling par l'utilisation de l'entretien motivationnel (de base).\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n 2019.\n \n\n\n\n
\n\n\n\n \n \n \"FormationPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@misc{noauthor_formation_2019,\n\ttitle = {Formation {ENA} : {Optimisation} de la pratique de counseling par l'utilisation de l'entretien motivationnel (de base)},\n\turl = {https://fcp.rtss.qc.ca/enrol/index.php?id=2387},\n\tlanguage = {fr-ca},\n\turldate = {2023-02-14},\n\tjournal = {Environnement numérique d'apprentissage},\n\tyear = {2019},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Provincial Guideline for the Clinical Management of High-Risk Drinking and Alcohol Use Disorder.\n \n \n \n \n\n\n \n British Columbia Centre on Substance Use\n\n\n \n\n\n\n December 2019.\n \n\n\n\n
\n\n\n\n \n \n \"ProvincialPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 6 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{british_columbia_centre_on_substance_use_provincial_2019,\n\ttitle = {Provincial {Guideline} for the {Clinical} {Management} of {High}-{Risk} {Drinking} and {Alcohol} {Use} {Disorder}},\n\turl = {https://www.bccsu.ca/wp-content/uploads/2021/01/AUD-Guideline.pdf},\n\turldate = {2020-09-28},\n\tauthor = {{British Columbia Centre on Substance Use}},\n\tmonth = dec,\n\tyear = {2019},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Lignes directrices nationales de l’Initiative canadienne de recherche sur l’abus de substances.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance; and Institut de recherche en santé du Canada\n\n\n \n\n\n\n 2019.\n \n\n\n\n
\n\n\n\n \n \n \"LignesPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 8 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_lignes_2019,\n\ttitle = {Lignes directrices nationales de l’{Initiative} canadienne de recherche sur l’abus de substances},\n\turl = {http://cran.qc.ca/sites/default/files/recommendations_fr_final.pdf},\n\turldate = {2019-08-16},\n\tauthor = {{Initiative canadienne de recherche en abus de substance} and {Institut de recherche en santé du Canada}},\n\tyear = {2019},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Le carnet de route: un outil clinique de collaboration.\n \n \n \n \n\n\n \n Sauvé, M.; Gravel-Simard, K.; and Giguère-Allard, M.\n\n\n \n\n\n\n 2019.\n \n\n\n\n
\n\n\n\n \n \n \"LePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 3 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{sauve_carnet_2019,\n\ttitle = {Le carnet de route: un outil clinique de collaboration},\n\turl = {https://www.bibliothequeduchum.ca/projets/tc/carnet_de_route_20190308.pdf},\n\tabstract = {Se débarrasser d’une habitude de consommation qui nuit à sa santé physique et mentale et à sa qualité de vie est rarement facile. La route est souvent longue et pleine d’embuches. Par contre, changer votre trajet de vie est possible. Ce carnet vous propose un itinéraire et divers outils qui pourront vous aider à arrêter ou à réduire votre consommation. Bonne route!},\n\turldate = {2019-08-16},\n\tauthor = {Sauvé, Monique and Gravel-Simard, Kim and Giguère-Allard, Mathieu},\n\tyear = {2019},\n\tkeywords = {Outils d'intervention},\n}\n\n
\n
\n\n\n
\n Se débarrasser d’une habitude de consommation qui nuit à sa santé physique et mentale et à sa qualité de vie est rarement facile. La route est souvent longue et pleine d’embuches. Par contre, changer votre trajet de vie est possible. Ce carnet vous propose un itinéraire et divers outils qui pourront vous aider à arrêter ou à réduire votre consommation. Bonne route!\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n First-Episode Psychosis and Co-Occurring Substance Use Disorders.\n \n \n \n \n\n\n \n Substance Abuse; and Administration, M. H. S.\n\n\n \n\n\n\n 2019.\n \n\n\n\n
\n\n\n\n \n \n \"First-EpisodePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{substance_abuse_and_mental_health_services_administration_first-episode_2019,\n\ttitle = {First-{Episode} {Psychosis} and {Co}-{Occurring} {Substance} {Use} {Disorders}},\n\turl = {https://store.samhsa.gov/system/files/pep19-pl-guide-3.pdf},\n\turldate = {2019-10-24},\n\tauthor = {{Substance Abuse and Mental Health Services Administration}},\n\tyear = {2019},\n\tkeywords = {Implantation de bonnes pratiques et de services intégrés},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2018\n \n \n (10)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Treatment of Personality Disorders in Adults with or without Comorbid Mental Health Conditions: Clinical Effectiveness and Guidelines.\n \n \n \n \n\n\n \n CADTH\n\n\n \n\n\n\n Technical Report 2018.\n \n\n\n\n
\n\n\n\n \n \n \"TreatmentPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@techreport{cadth_treatment_2018,\n\ttype = {Rapid {Response} {Report}},\n\ttitle = {Treatment of {Personality} {Disorders} in {Adults} with or without {Comorbid} {Mental} {Health} {Conditions}: {Clinical} {Effectiveness} and {Guidelines}},\n\turl = {https://cadth.ca/sites/default/files/pdf/htis/2018/RB1199%20Personality%20Disorders%20Final.pdf},\n\turldate = {2022-04-26},\n\tauthor = {CADTH},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Recommandations canadiennes pour l’usage du cannabis à moindre risque (RUCMR).\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance\n\n\n \n\n\n\n 2018.\n \n\n\n\n
\n\n\n\n \n \n \"RecommandationsPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_recommandations_2018,\n\ttitle = {Recommandations canadiennes pour l’usage du cannabis à moindre risque ({RUCMR})},\n\turl = {https://www.camh.ca/-/media/files/pdfs---reports-and-books---research/canadas-lower-risk-guidelines-cannabis-fr.pdf},\n\turldate = {2019-10-03},\n\tauthor = {{Initiative canadienne de recherche en abus de substance}},\n\tyear = {2018},\n\tkeywords = {Outils d'intervention},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Maitrise ton hit : S'injecter à moindre risque.\n \n \n \n \n\n\n \n pour la promotion de la santé des personnes utilisatrices de drogues , L. Q.\n\n\n \n\n\n\n 2018.\n \n\n\n\n
\n\n\n\n \n \n \"MaitrisePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{lassociation_quebecoise_pour_la_promotion_de_la_sante_des_personnes_utilisatrices_de_drogues_maitrise_2018,\n\ttitle = {Maitrise ton hit : {S}'injecter à moindre risque},\n\turl = {https://aqpsud.org/wp-content/uploads/2018/12/MTH_detaille_AQPSUD_2018_web_light.pdf},\n\turldate = {2022-02-18},\n\tauthor = {L’Association Québécoise pour la promotion de la santé des personnes utilisatrices de drogues},\n\tyear = {2018},\n\tkeywords = {Outils d'intervention},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n La schizophrénie : Guide d’information.\n \n \n \n \n\n\n \n Ernest, D.; Vuksic, O.; Shepard-Smith, A.; and Webb, E.\n\n\n \n\n\n\n Technical Report CAMH, 2018.\n \n\n\n\n
\n\n\n\n \n \n \"LaPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@techreport{ernest_schizophrenie_2018,\n\ttitle = {La schizophrénie : {Guide} d’information},\n\turl = {https://www.camh.ca/-/media/files/guides-and-publications-french/schizophrenia-guide-fr.pdf},\n\turldate = {2022-03-07},\n\tinstitution = {CAMH},\n\tauthor = {Ernest, Debbie and Vuksic, Olga and Shepard-Smith, Ashley and Webb, Emily},\n\tyear = {2018},\n\tkeywords = {Documents généraux sur les troubles concomitants},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Guide de pratique pour le traitement cognitif-comportemental des troubles psychotiques.\n \n \n \n \n\n\n \n Paquette Houde, C.; Abdel Baki, A.; Lecomte, T.; Lussier-Valade, M.; and Ngô, T.\n\n\n \n\n\n\n Technical Report 2018.\n \n\n\n\n
\n\n\n\n \n \n \"GuidePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@techreport{paquette_houde_guide_2018,\n\ttitle = {Guide de pratique pour le traitement cognitif-comportemental des troubles psychotiques},\n\turl = {https://tccmontreal.files.wordpress.com/2018/10/guidetccp_16-final-22-10-2018-version-isbn.pdf},\n\turldate = {2022-03-07},\n\tauthor = {Paquette Houde, C. and Abdel Baki, A. and Lecomte, T. and Lussier-Valade, M. and Ngô, T.L.},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.\n \n \n \n \n\n\n \n Crunelle, C. L.; van den Brink, W.; Moggi, F.; Konstenius, M.; Franck, J.; Levin, F. R.; van de Glind, G.; Demetrovics, Z.; Coetzee, C.; Luderer, M.; Schellekens, A.; ICASA consensus group; and Matthys, F.\n\n\n \n\n\n\n European Addiction Research, 24(1): 43–51. 2018.\n \n\n\n\n
\n\n\n\n \n \n \"InternationalPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@article{crunelle_international_2018,\n\ttitle = {International {Consensus} {Statement} on {Screening}, {Diagnosis} and {Treatment} of {Substance} {Use} {Disorder} {Patients} with {Comorbid} {Attention} {Deficit}/{Hyperactivity} {Disorder}},\n\tvolume = {24},\n\tissn = {1421-9891},\n\turl = {https://pubmed.ncbi.nlm.nih.gov/29510390/},\n\tdoi = {10.1159/000487767},\n\tabstract = {Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity.},\n\tlanguage = {eng},\n\tnumber = {1},\n\tjournal = {European Addiction Research},\n\tauthor = {Crunelle, Cleo L. and van den Brink, Wim and Moggi, Franz and Konstenius, Maija and Franck, Johan and Levin, Frances R. and van de Glind, Geurt and Demetrovics, Zsolt and Coetzee, Corné and Luderer, Mathias and Schellekens, Arnt and {ICASA consensus group} and Matthys, Frieda},\n\tyear = {2018},\n\tpmid = {29510390},\n\tpmcid = {PMC5986068},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n\tpages = {43--51},\n}\n\n
\n
\n\n\n
\n Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Buprénorphine (chlorhydarte de) (ProbuphineMC) : Demande d’autorisation de paiement pour les médicaments d’exception \\textbar Traitement substitutif de la dépendance aux opioïdes.\n \n \n \n \n\n\n \n RAMQ\n\n\n \n\n\n\n 2018.\n \n\n\n\n
\n\n\n\n \n \n \"BuprénorphinePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{ramq_buprenorphine_2018,\n\ttitle = {Buprénorphine (chlorhydarte de) ({ProbuphineMC}) : {Demande} d’autorisation de paiement pour les médicaments d’exception {\\textbar} {Traitement} substitutif de la dépendance aux opioïdes},\n\turl = {https://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/formulaires/8210.pdf},\n\turldate = {2020-06-10},\n\tauthor = {{RAMQ}},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n PROBUPHINE – Traitement substitutif de la dépendance aux opioïdes Avis transmis au ministre en septembre 2018.\n \n \n \n \n\n\n \n INESSS\n\n\n \n\n\n\n Technical Report 2018.\n \n\n\n\n
\n\n\n\n \n \n \"PROBUPHINEPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@techreport{inesss_probuphine_2018,\n\ttitle = {{PROBUPHINE} – {Traitement} substitutif de la dépendance aux opioïdes {Avis} transmis au ministre en septembre 2018},\n\turl = {https://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Avis_au_ministre/Octobre_2018/Probuphine_2018_09.pdf},\n\tauthor = {{INESSS}},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Administration de la naloxone par voie nasale.\n \n \n \n \n\n\n \n Institut national d'excellence en santé et en services sociaux\n\n\n \n\n\n\n 2018.\n \n\n\n\n
\n\n\n\n \n \n \"AdministrationPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{institut_national_dexcellence_en_sante_et_en_services_sociaux_administration_2018,\n\ttitle = {Administration de la naloxone par voie nasale},\n\turl = {https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/Naloxone_NAS_12-FR.pdf},\n\turldate = {2019-09-19},\n\tauthor = {{Institut national d'excellence en santé et en services sociaux}},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Administration de la naloxone par injection.\n \n \n \n \n\n\n \n Institut national d'excellence en santé et en services sociaux\n\n\n \n\n\n\n 2018.\n \n\n\n\n
\n\n\n\n \n \n \"AdministrationPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{institut_national_dexcellence_en_sante_et_en_services_sociaux_administration_2018-1,\n\ttitle = {Administration de la naloxone par injection},\n\turl = {https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/Naloxone_INJ_12-FR.pdf},\n\turldate = {2019-09-19},\n\tauthor = {{Institut national d'excellence en santé et en services sociaux}},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2016\n \n \n (2)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Les troubles anxieux : Guide d'information.\n \n \n \n \n\n\n \n CAMH\n\n\n \n\n\n\n 2016.\n \n\n\n\n
\n\n\n\n \n \n \"LesPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{camh_troubles_2016,\n\ttitle = {Les troubles anxieux : {Guide} d'information},\n\turl = {https://www.camh.ca/-/media/files/guides-and-publications-french/anxiety-guide-fr.pdf},\n\turldate = {2022-11-08},\n\tauthor = {CAMH},\n\tyear = {2016},\n\tkeywords = {Documents généraux sur les troubles concomitants},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Le trouble obsessionnel compulsif : Guide d’information.\n \n \n \n \n\n\n \n CAMH\n\n\n \n\n\n\n 2016.\n \n\n\n\n
\n\n\n\n \n \n \"LePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@book{camh_trouble_2016,\n\ttitle = {Le trouble obsessionnel compulsif : {Guide} d’information},\n\tisbn = {978-1-77114-354-7},\n\turl = {https://www.camh.ca/-/media/files/guides-and-publications-french/ocd-guide-fr.pdf},\n\turldate = {2023-01-17},\n\tauthor = {CAMH},\n\tyear = {2016},\n\tkeywords = {Documents généraux sur les troubles concomitants},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2015\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Plan d’action en santé mentale 2015‐2020 ‐ Faire ensemble et autrement.\n \n \n \n \n\n\n \n Ministère de la Santé et des Services sociaux\n\n\n \n\n\n\n 2015.\n \n\n\n\n
\n\n\n\n \n \n \"PlanPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{ministere_de_la_sante_et_des_services_sociaux_plan_2015,\n\ttitle = {Plan d’action en santé mentale 2015‐2020 ‐ {Faire} ensemble et autrement},\n\turl = {https://publications.msss.gouv.qc.ca/msss/fichiers/2017/17-914-17W.pdf},\n\tlanguage = {français},\n\tpublisher = {Gouvernement du Québec},\n\tauthor = {{Ministère de la Santé et des Services sociaux}},\n\tyear = {2015},\n\tkeywords = {Documents généraux sur les troubles concomitants},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2014\n \n \n (2)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n SAGE USAGE : Un programme qui s’adapte à la culture des Premières Nations et des Inuits.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n 2014.\n \n\n\n\n
\n\n\n\n \n \n \"SAGEPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{noauthor_sage_2014,\n\ttitle = {{SAGE} {USAGE} : {Un} programme qui s’adapte à la culture des {Premières} {Nations} et des {Inuits}},\n\turl = {https://iud.quebec/sites/iud/files/media/document/Pr%C3%A9sentation%2014%20d%C3%A9ecembre_finale.pdf},\n\turldate = {2023-01-31},\n\tjournal = {Institut universitaire sur les dépendances},\n\tyear = {2014},\n\tkeywords = {Organisation des services},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Les soins sensibles au traumatisme.\n \n \n \n \n\n\n \n Centre canadien de lutte contre les toxicomanies\n\n\n \n\n\n\n 2014.\n \n\n\n\n
\n\n\n\n \n \n \"LesPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{centre_canadien_de_lutte_contre_les_toxicomanies_soins_2014,\n\ttitle = {Les soins sensibles au traumatisme},\n\turl = {https://www.ccsa.ca/sites/default/files/2019-04/CCSA-Trauma-informed-Care-Toolkit-2014-fr.pdf},\n\tauthor = {{Centre canadien de lutte contre les toxicomanies}},\n\tyear = {2014},\n\tkeywords = {Implantation de bonnes pratiques et de services intégrés},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2012\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Notions de base sur les maladies mentales : guide pratique d'intervention.\n \n \n \n \n\n\n \n Institut universitaire en santé mentale de Québec\n\n\n \n\n\n\n 2012.\n \n\n\n\n
\n\n\n\n \n \n \"NotionsPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 4 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{institut_universitaire_en_sante_mentale_de_quebec_notions_2012,\n\ttitle = {Notions de base sur les maladies mentales : guide pratique d'intervention},\n\turl = {https://www.ciusss-capitalenationale.gouv.qc.ca/sites/default/files/guide-notions-bases-maladies-mentales.pdf},\n\tauthor = {{Institut universitaire en santé mentale de Québec}},\n\tyear = {2012},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2011\n \n \n (2)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n Du trouble mental à l'incapacité au travail: une perspective transdisciplinaire qui vise à mieux saisir cette problématique et à offrir des pistes d'intervention.\n \n \n \n\n\n \n Corbière, M.; and Durand, M.,\n editors.\n \n\n\n \n\n\n\n Presses de l'Université du Québec, Québec, Québec, 2011.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@book{corbiere_du_2011,\n\taddress = {Québec, Québec},\n\ttitle = {Du trouble mental à l'incapacité au travail: une perspective transdisciplinaire qui vise à mieux saisir cette problématique et à offrir des pistes d'intervention},\n\tisbn = {978-2-7605-2547-4},\n\tshorttitle = {Du trouble mental à l'incapacité au travail},\n\tpublisher = {Presses de l'Université du Québec},\n\teditor = {Corbière, Marc and Durand, Marie-José},\n\tyear = {2011},\n\tkeywords = {Documents généraux sur les troubles concomitants},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Dual Diagnosis Capability in Mental Health Treatment (DDCMHT) Toolkit Version 4.0.\n \n \n \n \n\n\n \n Substance Abuse; and Administration, M. H. S.\n\n\n \n\n\n\n 2011.\n \n\n\n\n
\n\n\n\n \n \n \"DualPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{substance_abuse_and_mental_health_services_administration_dual_2011,\n\ttitle = {Dual {Diagnosis} {Capability} in {Mental} {Health} {Treatment} ({DDCMHT}) {Toolkit} {Version} 4.0},\n\turl = {https://www.centerforebp.case.edu/client-files/pdf/ddcmhttoolkit.pdf},\n\tauthor = {{Substance Abuse and Mental Health Services Administration}},\n\tyear = {2011},\n\tkeywords = {Implantation de bonnes pratiques et de services intégrés},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2010\n \n \n (5)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Antisocial Personality Disorder: Treatment, Management and Prevention.\n \n \n \n \n\n\n \n National Collaborating Centre for Mental Health (UK)\n\n\n \n\n\n\n of National Institute for Health and Clinical Excellence: GuidanceBritish Psychological Society, Leicester (UK), 2010.\n \n\n\n\n
\n\n\n\n \n \n \"AntisocialPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@book{national_collaborating_centre_for_mental_health_uk_antisocial_2010,\n\taddress = {Leicester (UK)},\n\tseries = {National {Institute} for {Health} and {Clinical} {Excellence}: {Guidance}},\n\ttitle = {Antisocial {Personality} {Disorder}: {Treatment}, {Management} and {Prevention}},\n\tcopyright = {Copyright © 2010, The British Psychological Society \\& The Royal College of Psychiatrists.},\n\tisbn = {978-1-85433-478-7},\n\tshorttitle = {Antisocial {Personality} {Disorder}},\n\turl = {http://www.ncbi.nlm.nih.gov/books/NBK55345/},\n\tabstract = {The guideline on Antisocial Personality Disorder, commissioned by NICE and developed by the National Collaborating Centre for Mental Health, sets out clear, evidence- and consensus-based recommendations for staff working in health and social care and the criminal justice system on how to treat, manage and prevent antisocial personality disorder. The NICE guideline takes the first comprehensive view of antisocial personality disorder and is an invaluable resource to enable professionals to improve the outcomes for people with the disorder, who often have significant impairments. Being able to prevent and properly manage antisocial personality disorder will also have considerable social implications. This publication brings together all of the evidence that led to the recommendations in the NICE guideline, and draws on a wide literature, including evidence for the management of offending behaviour. It includes a review of interventions in children and young people with conduct disorder, which may prevent the development of antisocial personality disorder; risk assessment and management; organisation and experience of care; and a range of interventions for adults with antisocial personality disorder, including psychological interventions, treatment for comorbid disorders, therapeutic communities and pharmacological interventions. The book also contains a useful overview of antisocial personality disorder, including ethical considerations.},\n\tlanguage = {eng},\n\turldate = {2023-08-24},\n\tpublisher = {British Psychological Society},\n\tauthor = {{National Collaborating Centre for Mental Health (UK)}},\n\tyear = {2010},\n\tpmid = {21834198},\n\tkeywords = {Documents généraux sur les troubles concomitants},\n}\n\n
\n
\n\n\n
\n The guideline on Antisocial Personality Disorder, commissioned by NICE and developed by the National Collaborating Centre for Mental Health, sets out clear, evidence- and consensus-based recommendations for staff working in health and social care and the criminal justice system on how to treat, manage and prevent antisocial personality disorder. The NICE guideline takes the first comprehensive view of antisocial personality disorder and is an invaluable resource to enable professionals to improve the outcomes for people with the disorder, who often have significant impairments. Being able to prevent and properly manage antisocial personality disorder will also have considerable social implications. This publication brings together all of the evidence that led to the recommendations in the NICE guideline, and draws on a wide literature, including evidence for the management of offending behaviour. It includes a review of interventions in children and young people with conduct disorder, which may prevent the development of antisocial personality disorder; risk assessment and management; organisation and experience of care; and a range of interventions for adults with antisocial personality disorder, including psychological interventions, treatment for comorbid disorders, therapeutic communities and pharmacological interventions. The book also contains a useful overview of antisocial personality disorder, including ethical considerations.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Aide-mémoire – LPP : les différents types de garde.\n \n \n \n \n\n\n \n du Québec, T. A.\n\n\n \n\n\n\n 2010.\n \n\n\n\n
\n\n\n\n \n \n \"Aide-mémoirePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{tribunal_administratif_du_quebec_aide-memoire_2010,\n\ttitle = {Aide-mémoire – {LPP} : les différents types de garde},\n\turl = {https://bibliothequeduchum.ca/projets/tc/documents/aide-memoire.pdf},\n\tauthor = {Tribunal Administratif du Québec},\n\tyear = {2010},\n\tkeywords = {Organisation des services},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Implementing Integrated Mental Health and Substance Abuse Services.\n \n \n \n \n\n\n \n Robert E. Drake MD, P.; and PhD, G. R. B.\n\n\n \n\n\n\n Journal of Dual Diagnosis, 6(3-4): 251–262. December 2010.\n \n\n\n\n
\n\n\n\n \n \n \"ImplementingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@article{robert_e_drake_md_implementing_2010,\n\ttitle = {Implementing {Integrated} {Mental} {Health} and {Substance} {Abuse} {Services}},\n\tvolume = {6},\n\tissn = {1550-4263},\n\turl = {https://doi.org/10.1080/15504263.2010.540772},\n\tdoi = {10.1080/15504263.2010.540772},\n\tabstract = {This review addresses implementation strategies related to integrated treatment for people with co-occurring serious mental illness and substance use disorder. The dominant model over recent years emphasizes the regional technical assistance center as a resource for planning, training, supervision, monitoring, and problem solving. Technical assistance centers have not been formally evaluated. Future implementation studies will rely strongly on learning collaboratives and modern information technology, including comprehensive electronic decision support systems. (Journal of Dual Diagnosis, 6:251–262, 2010)},\n\tnumber = {3-4},\n\turldate = {2019-06-13},\n\tjournal = {Journal of Dual Diagnosis},\n\tauthor = {Robert E. Drake MD, PhD and PhD, Gary R. Bond},\n\tmonth = dec,\n\tyear = {2010},\n\tkeywords = {Implantation de bonnes pratiques et de services intégrés},\n\tpages = {251--262},\n}\n\n
\n
\n\n\n
\n This review addresses implementation strategies related to integrated treatment for people with co-occurring serious mental illness and substance use disorder. The dominant model over recent years emphasizes the regional technical assistance center as a resource for planning, training, supervision, monitoring, and problem solving. Technical assistance centers have not been formally evaluated. Future implementation studies will rely strongly on learning collaboratives and modern information technology, including comprehensive electronic decision support systems. (Journal of Dual Diagnosis, 6:251–262, 2010)\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Implementing Integrated Mental Health and Substance Abuse Services.\n \n \n \n \n\n\n \n Robert E. Drake MD, P.; and PhD, G. R. B.\n\n\n \n\n\n\n Journal of Dual Diagnosis, 6(3-4): 251–262. December 2010.\n \n\n\n\n
\n\n\n\n \n \n \"ImplementingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@article{robert_e_drake_md_implementing_2010-1,\n\ttitle = {Implementing {Integrated} {Mental} {Health} and {Substance} {Abuse} {Services}},\n\tvolume = {6},\n\tissn = {1550-4263},\n\turl = {https://doi.org/10.1080/15504263.2010.540772},\n\tdoi = {10.1080/15504263.2010.540772},\n\tabstract = {This review addresses implementation strategies related to integrated treatment for people with co-occurring serious mental illness and substance use disorder. The dominant model over recent years emphasizes the regional technical assistance center as a resource for planning, training, supervision, monitoring, and problem solving. Technical assistance centers have not been formally evaluated. Future implementation studies will rely strongly on learning collaboratives and modern information technology, including comprehensive electronic decision support systems. (Journal of Dual Diagnosis, 6:251–262, 2010)},\n\tnumber = {3-4},\n\turldate = {2019-08-16},\n\tjournal = {Journal of Dual Diagnosis},\n\tauthor = {Robert E. Drake MD, PhD and PhD, Gary R. Bond},\n\tmonth = dec,\n\tyear = {2010},\n\tkeywords = {Implantation de bonnes pratiques et de services intégrés},\n\tpages = {251--262},\n}\n\n
\n
\n\n\n
\n This review addresses implementation strategies related to integrated treatment for people with co-occurring serious mental illness and substance use disorder. The dominant model over recent years emphasizes the regional technical assistance center as a resource for planning, training, supervision, monitoring, and problem solving. Technical assistance centers have not been formally evaluated. Future implementation studies will rely strongly on learning collaboratives and modern information technology, including comprehensive electronic decision support systems. (Journal of Dual Diagnosis, 6:251–262, 2010)\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Routes to recovery: psychosocial interventions for drug misuse: a framework and toolkit for implementing NICE recommended treatment interventions.\n \n \n \n \n\n\n \n NHS National Treatment Agency for Substance Misuse\n\n\n \n\n\n\n 2010.\n \n\n\n\n
\n\n\n\n \n \n \"RoutesPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{nhs_national_treatment_agency_for_substance_misuse_routes_2010,\n\ttitle = {Routes to recovery: psychosocial interventions for drug misuse: a framework and toolkit for implementing {NICE} recommended treatment interventions},\n\turl = {https://www.bl.uk/collection-items/routes-to-recovery-psychosocial-interventions-for-drug-misuse-a-framework-and-toolkit-for-implementing-nicerecommended-treatment-interventions},\n\tabstract = {Toolkit for use of psychosocial interventions in management of drug misuse and common mental health problems},\n\tlanguage = {eng},\n\turldate = {2020-10-20},\n\tpublisher = {The British Library},\n\tauthor = {{NHS National Treatment Agency for Substance Misuse}},\n\tyear = {2010},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n
\n Toolkit for use of psychosocial interventions in management of drug misuse and common mental health problems\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2009\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n La buprénorphine dans le traitement de la dépendance aux opioïdes : lignes directrices.\n \n \n \n \n\n\n \n Collège des médecins du Québec; and Ordre des pharmaciens du Québec\n\n\n \n\n\n\n 2009.\n \n\n\n\n
\n\n\n\n \n \n \"LaPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{college_des_medecins_du_quebec_buprenorphine_2009,\n\ttitle = {La buprénorphine dans le traitement de la dépendance aux opioïdes : lignes directrices},\n\turl = {https://www.opq.org/doc/media/808_38_fr-ca_0_ld_buprenorphone.pdf},\n\turldate = {2020-04-20},\n\tauthor = {{Collège des médecins du Québec} and {Ordre des pharmaciens du Québec}},\n\tyear = {2009},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n undefined\n \n \n (22)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Grille d'évaluation de la personne à risque suicidaire.\n \n \n \n \n\n\n \n québécoise des infirmières et infirmiers en santé mentale , A.\n\n\n \n\n\n\n Technical Report .\n \n\n\n\n
\n\n\n\n \n \n \"GrillePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@techreport{association_quebecoise_des_infirmieres_et_infirmiers_en_sante_mentale_grille_nodate,\n\ttitle = {Grille d'évaluation de la personne à risque suicidaire},\n\turl = {https://aqiism.org/wp-content/uploads/Outil-clinique-Guide-d%C3%A9valuation-du-risque-suicidaire-_-m%C3%A0j-09-2019.pdf},\n\turldate = {2022-02-15},\n\tauthor = {Association québécoise des infirmières et infirmiers en santé mentale},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Trouble lié à l'usage d'alcool.\n \n \n \n \n\n\n \n INESSS\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"TroublePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{inesss_trouble_nodate,\n\ttitle = {Trouble lié à l'usage d'alcool},\n\turl = {https://tinyurl.com/5wf455dr},\n\tlanguage = {fr-CA},\n\turldate = {2021-11-22},\n\tjournal = {INESSS},\n\tauthor = {INESSS},\n\tkeywords = {Documents généraux sur les troubles concomitants},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Thérapie cognitivo-comportementale: guides de pratiques et autres outils.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"ThérapiePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{noauthor_therapie_nodate,\n\ttitle = {Thérapie cognitivo-comportementale: guides de pratiques et autres outils},\n\turl = {https://tccmontreal.com/},\n\tlanguage = {fr-CA},\n\turldate = {2022-11-15},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Modèle de protocole de mise sous garde en établissement de santé et de services sociaux des personnes dangereuses pour elles-mêmes ou pour autrui en raison de leur état mental.\n \n \n \n \n\n\n \n Ministère de la Santé et des Services sociaux\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"ModèlePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{ministere_de_la_sante_et_des_services_sociaux_modeprotocole_nodate,\n\ttitle = {Modèle de protocole de mise sous garde en établissement de santé et de services sociaux des personnes dangereuses pour elles-mêmes ou pour autrui en raison de leur état mental},\n\turl = {https://publications.msss.gouv.qc.ca/msss/document-002234/},\n\turldate = {2023-08-24},\n\tauthor = {{Ministère de la Santé et des Services sociaux}},\n\tkeywords = {Organisation des services},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Implementing Seeking Safety therapy for PTSD and substance abuse: Clinical Guidelines.\n \n \n \n \n\n\n \n Najavits, L. M.\n\n\n \n\n\n\n Technical Report .\n \n\n\n\n
\n\n\n\n \n \n \"ImplementingPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@techreport{najavits_implementing_nodate,\n\ttitle = {Implementing {Seeking} {Safety} therapy for {PTSD} and substance abuse: {Clinical} {Guidelines}},\n\turl = {http://citeseerx.ist.psu.edu/viewdoc/download;jsessionid=4923A1F071BC9F7D6977BB8D1574CB07?doi=10.1.1.152.3287&rep=rep1&type=pdf},\n\turldate = {2022-04-19},\n\tauthor = {Najavits, Lisa M.},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Justice et santé mentale : une alternative à l’emprisonnement.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"JusticePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{noauthor_justice_nodate,\n\ttitle = {Justice et santé mentale : une alternative à l’emprisonnement},\n\tshorttitle = {Justice et santé mentale},\n\turl = {https://www.quebec.ca/nouvelles/actualites/details/sante-mentale-alternative-emprisonnement},\n\tabstract = {En matière de santé mentale, l’emprisonnement ne règle souvent rien. Solution pour enrayer le phénomène dit des portes tournantes.},\n\tlanguage = {fr},\n\turldate = {2023-03-21},\n\tjournal = {Gouvernement du Québec},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n
\n En matière de santé mentale, l’emprisonnement ne règle souvent rien. Solution pour enrayer le phénomène dit des portes tournantes.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Journal des symptômes et des activités.\n \n \n \n \n\n\n \n L'Association pour la santé environnementale du Québec\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"JournalPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{lassociation_pour_la_sante_environnementale_du_quebec_journal_nodate,\n\ttitle = {Journal des symptômes et des activités},\n\turl = {https://aseq-ehaq.ca/pdf/Journal-des-symptomes-et-des-expositions.pdf},\n\turldate = {2022-10-03},\n\tauthor = {{L'Association pour la santé environnementale du Québec}},\n\tkeywords = {Outils d'intervention},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Être non criminellement responsable en raison de troubles mentaux.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"ÊtrePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{noauthor_etre_nodate,\n\ttitle = {Être non criminellement responsable en raison de troubles mentaux},\n\turl = {https://educaloi.qc.ca/capsules/non-criminellement-responsable-troubles-mentaux/},\n\tabstract = {Une des raisons pour lesquelles les personnes ayant commis des crimes sont punies est qu’elles ont « choisi » de poser un acte immoral. Cependant, certaines personnes ayant un trouble mental ne peuvent pas faire la différence entre le bien et le mal. Le système de justice canadien prévoit que ces personnes devraient être traitées pour leur […]},\n\tlanguage = {fr-FR},\n\turldate = {2023-05-16},\n\tjournal = {Éducaloi},\n\tkeywords = {Organisation des services},\n}\n\n
\n
\n\n\n
\n Une des raisons pour lesquelles les personnes ayant commis des crimes sont punies est qu’elles ont « choisi » de poser un acte immoral. Cependant, certaines personnes ayant un trouble mental ne peuvent pas faire la différence entre le bien et le mal. Le système de justice canadien prévoit que ces personnes devraient être traitées pour leur […]\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Algorithme de prise en charge de la douleur neuropathique - Publications du ministère de la Santé et des Services sociaux.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"AlgorithmePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{noauthor_algorithme_nodate,\n\ttitle = {Algorithme de prise en charge de la douleur neuropathique - {Publications} du ministère de la {Santé} et des {Services} sociaux},\n\turl = {https://publications.msss.gouv.qc.ca/msss/document-001058/},\n\turldate = {2023-04-14},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Demander au tribunal une ordonnance pour évaluation psychiatrique.\n \n \n \n \n\n\n \n Gouvernement du Québec\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"DemanderPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{gouvernement_du_quebec_demander_nodate,\n\ttitle = {Demander au tribunal une ordonnance pour évaluation psychiatrique},\n\turl = {http://www4.gouv.qc.ca/fr/Portail/citoyens/programme-service/Pages/Info.aspx?sqctype=service&sqcid=1050},\n\turldate = {2019-11-29},\n\tauthor = {{Gouvernement du Québec}},\n\tkeywords = {Organisation des services},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n TEST.\n \n \n \n\n\n \n \n\n\n \n\n\n\n .\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@book{noauthor_test_nodate,\n\ttitle = {{TEST}},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Consentir à des soins de santé en cas d'inaptitude.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"ConsentirPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{noauthor_consentir_nodate,\n\ttitle = {Consentir à des soins de santé en cas d'inaptitude},\n\turl = {https://www.quebec.ca/famille-et-soutien-aux-personnes/inaptitude-perte-autonomie/consentement-soins-inaptitude},\n\tabstract = {Comment faire une demande de consentement au Curateur public. Personnes autorisées à consentir à des soins de santé au nom d’une personne inapte.},\n\tlanguage = {fr},\n\turldate = {2023-04-11},\n\tjournal = {Gouvernement du Québec},\n\tkeywords = {Outils d'intervention},\n}\n\n
\n
\n\n\n
\n Comment faire une demande de consentement au Curateur public. Personnes autorisées à consentir à des soins de santé au nom d’une personne inapte.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Copyright and Privacy in Photography.\n \n \n \n \n\n\n \n Samuelson-Glushko Canadian Internet Policy; and (CIPPIC), P. I. C.\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"CopyrightPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@misc{samuelson-glushko_canadian_internet_policy_and_public_interest_clinic_cippic_copyright_nodate,\n\ttitle = {Copyright and {Privacy} in {Photography}},\n\turl = {https://cippic.ca/en/FAQ/Photography_Law#distribute},\n\turldate = {2023-04-11},\n\tauthor = {{Samuelson-Glushko Canadian Internet Policy and Public Interest Clinic (CIPPIC)}},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Utilisation de l'image et de la voix des personnes.\n \n \n \n \n\n\n \n Bibliothèque de l'Université de Laval\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"UtilisationPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@misc{bibliotheque_de_luniversite_de_laval_utilisation_nodate,\n\ttitle = {Utilisation de l'image et de la voix des personnes},\n\turl = {https://www.bda.ulaval.ca/notions-en-droit-dauteur/utilisation-de-image-et-de-la-voix-des-personnes/},\n\tabstract = {La captation, la fixation et la diffusion de la voix et de l’image des personnes sans leur consentement peuvent constituer une atteinte à la vie privée.},\n\tlanguage = {fr-CA},\n\turldate = {2023-04-11},\n\tjournal = {Bureau du droit d'auteur},\n\tauthor = {{Bibliothèque de l'Université de Laval}},\n}\n\n
\n
\n\n\n
\n La captation, la fixation et la diffusion de la voix et de l’image des personnes sans leur consentement peuvent constituer une atteinte à la vie privée.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Guide sur le droit d'auteur.\n \n \n \n \n\n\n \n Bibliothèques - Université de Montréal\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"GuidePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@misc{bibliotheques_-_universite_de_montreal_guide_nodate,\n\ttitle = {Guide sur le droit d'auteur},\n\turl = {https://bib.umontreal.ca/gerer-diffuser/droit-auteur/guide-droit-auteur?tab=5240240},\n\tlanguage = {fr},\n\turldate = {2023-04-11},\n\tjournal = {Bibliothèques - Université de Montréal},\n\tauthor = {{Bibliothèques - Université de Montréal}},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Télémédecine pour le traitement des troubles liés à l'usage de substances psychoactives : Guide pratique national.\n \n \n \n \n\n\n \n Bruneau, J\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"TélémédecinePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@misc{bruneau_telemedecine_nodate,\n\ttitle = {Télémédecine pour le traitement des troubles liés à l'usage de substances psychoactives : {Guide} pratique national},\n\turl = {https://crism.ca/wp-content/uploads/2020/08/COVID19-LDPN-Telemedecine-01072020.pdf},\n\turldate = {2023-08-23},\n\tauthor = {Bruneau, J},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Aide mémoire pour l'intervention en dépendance en contexte de pandémie.\n \n \n \n \n\n\n \n Institut universitaire sur les dépendances\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"AidePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{institut_universitaire_sur_les_dependances_aide_nodate,\n\ttitle = {Aide mémoire pour l'intervention en dépendance en contexte de pandémie},\n\turl = {https://iud.quebec/sites/iud/files/media/document/Aide-m%C3%A9moire_0.pdf},\n\turldate = {2020-10-05},\n\tauthor = {{Institut universitaire sur les dépendances}},\n\tkeywords = {\\_COVID-19},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Le droit à l'image.\n \n \n \n \n\n\n \n Éducaloi\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"LePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@misc{educaloi_droit_nodate,\n\ttitle = {Le droit à l'image},\n\turl = {https://educaloi.qc.ca/capsules/le-droit-a-limage/},\n\tabstract = {Que signifie «droit à l’image» à l’ère des médias sociaux et des systèmes de reconnaissance faciale? Pouvez-vous empêcher la diffusion d’une image sur laquelle vous êtes reconnaissable? Une photo de vous, c’est personnel Personne ne peut utiliser une photo de vous à moins que vous ne lui permettiez de le faire. C’est votre droit à […]},\n\tlanguage = {fr-FR},\n\turldate = {2023-04-11},\n\tjournal = {Éducaloi},\n\tauthor = {Éducaloi},\n}\n\n
\n
\n\n\n
\n Que signifie «droit à l’image» à l’ère des médias sociaux et des systèmes de reconnaissance faciale? Pouvez-vous empêcher la diffusion d’une image sur laquelle vous êtes reconnaissable? Une photo de vous, c’est personnel Personne ne peut utiliser une photo de vous à moins que vous ne lui permettiez de le faire. C’est votre droit à […]\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Évaluation des syndromes de sevrage dans un établissement clinique selon l’échelle de l’alcoolisme (CIWA-Ar).\n \n \n \n \n\n\n \n MSD Manuals\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"ÉvaluationPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{msd_manuals_evaluation_nodate,\n\ttitle = {Évaluation des syndromes de sevrage dans un établissement clinique selon l’échelle de l’alcoolisme ({CIWA}-{Ar})},\n\turl = {https://www.msdmanuals.com/medical-calculators/CIWA-fr.htm},\n\turldate = {2020-06-11},\n\tauthor = {{MSD Manuals}},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Aptitude et consentement aux soins.\n \n \n \n \n\n\n \n Curateur public du Québec\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"AptitudePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@misc{curateur_public_du_quebec_aptitude_nodate,\n\ttitle = {Aptitude et consentement aux soins},\n\turl = {https://www.curateur.gouv.qc.ca/cura/publications/reseau_de_la_sante/mod03.pdf},\n\tauthor = {{Curateur public du Québec}},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Échelle COWS.\n \n \n \n \n\n\n \n Hôpitaux Universitaires Genève\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"ÉchellePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{hopitaux_universitaires_geneve_echelle_nodate,\n\ttitle = {Échelle {COWS}},\n\turl = {https://pro.addictohug.ch/cows/},\n\turldate = {2020-06-10},\n\tauthor = {{Hôpitaux Universitaires Genève}},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Dual Diagnosis Capability in Addiction Treatment (DDCAT) Toolkit.\n \n \n \n \n\n\n \n Substance Abuse; and Administration, M. H. S.\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"DualPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@misc{substance_abuse_and_mental_health_services_administration_dual_nodate,\n\ttitle = {Dual {Diagnosis} {Capability} in {Addiction} {Treatment} ({DDCAT}) {Toolkit}},\n\turl = {https://www.centerforebp.case.edu/client-files/pdf/ddcattoolkit.pdf},\n\tlanguage = {en},\n\tauthor = {{Substance Abuse and Mental Health Services Administration}},\n\tkeywords = {Implantation de bonnes pratiques et de services intégrés},\n}\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n\n\n\n
\n\n\n \n\n \n \n \n \n\n
\n"}; document.write(bibbase_data.data);